AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17296994 — intervention group
Group type: COMPARATOR
Intervention: Normal-appearing pyramidal tract (PYT) in RRMS patients
Number of subjects: 29
Study 17296994 — intervention group
Group type: COMPARATOR
Intervention: PYT lesions in RRMS patients
Number of subjects: 29
Study 17296994 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 29
Study 16272182 — intervention group
Group type: EXPERIMENTAL
Intervention: eptapirone 1.5mg at 10 AM
Number of subjects: 12
Study 16272182 — intervention group
Group type: EXPERIMENTAL
Intervention: eptapirone 1.5mg at 11 PM
Number of subjects: 12
Study 16272182 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone 20mg at 11 PM
Number of subjects: 12
Study 16272182 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 11900104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating-case words and pseudowords
Number of subjects: 0
Study 11900104 — intervention group
Group type: COMPARATOR
Intervention: Pure-case words and pseudowords
Number of subjects: 0
Study 10515037 — intervention group
Group type: EXPERIMENTAL
Intervention: rovamycin
Number of subjects: 249
Study 10515037 — intervention group
Group type: COMPARATOR
Intervention: metronidazole
Number of subjects: 249
Study 10515037 — intervention group
Group type: COMPARATOR
Intervention: tonidazol
Number of subjects: 249
Study 10515037 — intervention group
Group type: COMPARATOR
Intervention: amoxicilline
Number of subjects: 249
Study 10515037 — intervention group
Group type: COMPARATOR
Intervention: clarithromycin
Number of subjects: 249
Study 10515037 — intervention group
Group type: COMPARATOR
Intervention: omeprazole
Number of subjects: 249
Study 10515037 — intervention group
Group type: COMPARATOR
Intervention: azitromycin
Number of subjects: 249
Study 7548709 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage sequential design with variance-based weights for treatment effects
Number of subjects: 0
Study 7548709 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage crossover design
Number of subjects: 0
Study 7548709 — intervention group
Group type: COMPARATOR
Intervention: Usual crossover trial
Number of subjects: 0
Study 2044499 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Epilepsy Program (experimental group)
Number of subjects: 365
Study 2044499 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 365
Study 7011078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg every 6 hours)
Number of subjects: 135
Study 7011078 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid (Maalox, 10 ml/hour)
Number of subjects: 135
Study 7011078 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 135
Study 31318259 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Speaker
Number of subjects: 0
Study 31318259 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicational remembering in a looped serial transmission chain
Number of subjects: 0
Study 31318259 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Speaker's perceived group membership (ingroup vs outgroup)
Number of subjects: 0
Study 30526423 — intervention group
Group type: EXPERIMENTAL
Intervention: All-human operator configuration
Number of subjects: 3
Study 30526423 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-autonomy teams
Number of subjects: 3
Study 30526423 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned autonomy failures
Number of subjects: 3
Study 28560524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 24
Study 28560524 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 24
Study 28560524 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (normal weights and overweights)
Number of subjects: 24
Study 26643240 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium, 2.5 mg, 1/d for 11 d
Number of subjects: 36
Study 26643240 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin, 4100 U, 1/12 h for 11 d
Number of subjects: 36
Study 26643240 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium
Number of subjects: 36
Study 26643240 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin
Number of subjects: 36
Study 26643240 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 36
Study 24738240 — intervention group
Group type: EXPERIMENTAL
Intervention: cycloferon + lamivudine for 48 weeks
Number of subjects: 647
Study 24738240 — intervention group
Group type: COMPARATOR
Intervention: lamivudine + placebo for 48 weeks
Number of subjects: 647
Study 21372069 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral intervention
Number of subjects: 58
Study 21372069 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 58
Study 19644973 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 204
Study 19644973 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 204
Study 17653532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (7.5 mg)
Number of subjects: 18
Study 17653532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 18
Study 17653532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15853576 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (300 mg intravenous infusion, administered monthly)
Number of subjects: 0
Study 15853576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11881837 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg naftidrofuryl/day
Number of subjects: 0
Study 11881837 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg naftidrofuryl/day
Number of subjects: 0
Study 11881837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9777836 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet
Number of subjects: 12
Study 9777836 — intervention group
Group type: COMPARATOR
Intervention: Control group (female controls)
Number of subjects: 12
Study 9777836 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on exclusion diet
Number of subjects: 12
Study 9777836 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet after lactulose
Number of subjects: 12
Study 9777836 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 12
Study 7892744 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with curative intent for T2 stage patients
Number of subjects: 158
Study 7892744 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with curative intent for T3/T4 stage patients
Number of subjects: 158
Study 7892744 — intervention group
Group type: COMPARATOR
Intervention: Subclinical malignancy treated with radiotherapy
Number of subjects: 158
Study 3115770 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 129
Study 3115770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 29425387 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 70
Study 29425387 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 70
Study 27514859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Web-based health feedback
Number of subjects: 981
Study 27514859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Web-based health feedback + optional telephone coaching
Number of subjects: 981
Study 27514859 — intervention group
Group type: COMPARATOR
Intervention: No health feedback or telephone coaching (Control group A)
Number of subjects: 981
Study 26224765 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 350
Study 26224765 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 350
Study 23507346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic fitness program (6-week duration, twice a week)
Number of subjects: 43
Study 23507346 — intervention group
Group type: COMPARATOR
Intervention: Education-only group (1 educational session and a booklet)
Number of subjects: 43
Study 21042116 — intervention group
Group type: EXPERIMENTAL
Intervention: Avotermin 200 ng/100 μl/linear centimeter, administered once or twice
Number of subjects: 71
Study 21042116 — intervention group
Group type: EXPERIMENTAL
Intervention: Avotermin 50 ng/100 μl/linear centimeter, administered twice
Number of subjects: 71
Study 21042116 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no injection)
Number of subjects: 71
Study 18604623 — intervention group
Group type: EXPERIMENTAL
Intervention: Various definitions for excess body fat (age-independent cut points)
Number of subjects: 6205
Study 18604623 — intervention group
Group type: EXPERIMENTAL
Intervention: Various definitions for excess body fat (age-dependent cut points)
Number of subjects: 6205
Study 18604623 — intervention group
Group type: COMPARATOR
Intervention: Various definitions for excess body fat
Number of subjects: 6205
Study 16979687 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted head position (15 observers)
Number of subjects: 90
Study 16979687 — intervention group
Group type: COMPARATOR
Intervention: Erect position (15 observers)
Number of subjects: 90
Study 16979687 — intervention group
Group type: COMPARATOR
Intervention: Prism goggles (15 observers)
Number of subjects: 90
Study 16979687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bending head forward with goggles (15 observers)
Number of subjects: 90
Study 16979687 — intervention group
Group type: COMPARATOR
Intervention: Hollow goggles while lying on belly (15 observers)
Number of subjects: 90
Study 14609611 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic testosterone therapy
Number of subjects: 0
Study 12467086 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorization task without exposure to training sequence
Number of subjects: 0
Study 12467086 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification and recognition performance tested immediately or after a week delay
Number of subjects: 0
Study 12467086 — intervention group
Group type: COMPARATOR
Intervention: Cued-recall task
Number of subjects: 0
Study 12467086 — intervention group
Group type: COMPARATOR
Intervention: Categorization task
Number of subjects: 0
Study 9606843 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of fibrinolysis
Number of subjects: 0
Study 9606843 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of inhibitors and platelets hypoaggregation
Number of subjects: 0
Study 9606843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggravation of patient's state post-operation
Number of subjects: 0
Study 7949553 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 14
Study 7949553 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 14
Study 7949553 — intervention group
Group type: COMPARATOR
Intervention: Mild human immunodeficiency virus (HIV) encephalopathy patients
Number of subjects: 14
Study 7949553 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 14
Study 2453683 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 200 mg, administered orally the night before the operation, 2 to 4 hours preoperatively, and every 12 hours postoperatively for 36 hours.
Number of subjects: 40
Study 2453683 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered in the same manner as enoxacin.
Number of subjects: 40
Study 30957112 — intervention group
Group type: EXPERIMENTAL
Intervention: Curvature-analysis method
Number of subjects: 27
Study 30957112 — intervention group
Group type: COMPARATOR
Intervention: Line-drawing method
Number of subjects: 27
Study 30957112 — intervention group
Group type: COMPARATOR
Intervention: Powder-coating method
Number of subjects: 27
Study 28938446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU/wk for 12 weeks
Number of subjects: 98
Study 28938446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 25153574 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 28
Study 25153574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 25153574 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D patients
Number of subjects: 28
Study 23453347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 214
Study 23453347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 23453347 — intervention group
Group type: COMPARATOR
Intervention: Lithium vs Placebo
Number of subjects: 214
Study 21447515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho All‐Flex Diaphragm and lubricant gel (Replens) with condoms
Number of subjects: 2016
Study 21447515 — intervention group
Group type: COMPARATOR
Intervention: Condoms alone
Number of subjects: 2016
Study 18092150 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (TP) administered as intravenous bolus doses of 20 microg/kg every 6 h for a maximum of 96 h
Number of subjects: 58
Study 18092150 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 58
Study 18092150 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (TP)
Number of subjects: 58
Study 16580383 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day isoflavones
Number of subjects: 78
Study 16580383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 12743669 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone 500 microg (FP), 1 puff b.i.d.
Number of subjects: 15
Study 12743669 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 250 microg plus salmeterol 50 microg (FP+SM), 1 puff b.i.d.
Number of subjects: 15
Study 10683715 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium salt 50 mg in sachet (Voltfast)
Number of subjects: 24
Study 10683715 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium salt 50 mg in tablet (Cataflam)
Number of subjects: 24
Study 9086683 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Sensations Interpretation Questionnaire (BSIQ) administered to panic patients
Number of subjects: 0
Study 9086683 — intervention group
Group type: COMPARATOR
Intervention: Body Sensations Interpretation Questionnaire (BSIQ) administered to controls
Number of subjects: 0
Study 9086683 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief version of the BSIQ
Number of subjects: 0
Study 8229120 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 at doses > or = 2.5 micrograms/kg/d
Number of subjects: 28
Study 8229120 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 at doses 7.5 and 10 micrograms/kg
Number of subjects: 28
Study 8229120 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 at doses > or = 2.5 micrograms/kg
Number of subjects: 28
Study 8229120 — intervention group
Group type: COMPARATOR
Intervention: IL-3
Number of subjects: 28
Study 31321713 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)
Number of subjects: 2153
Study 31321713 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC)
Number of subjects: 2153
Study 31321713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI)
Number of subjects: 2153
Study 31321713 — intervention group
Group type: COMPARATOR
Intervention: Combination of FF/UMEC/VI
Number of subjects: 2153
Study 30691752 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-mobilization group
Number of subjects: 10
Study 30691752 — intervention group
Group type: COMPARATOR
Intervention: Late-mobilization group
Number of subjects: 10
Study 30691752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined joint mobilization and calf stretching
Number of subjects: 10
Study 28395185 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial behavior towards specific others
Number of subjects: 159
Study 28395185 — intervention group
Group type: COMPARATOR
Intervention: Prosocial behavior directed towards the world in general
Number of subjects: 159
Study 28395185 — intervention group
Group type: COMPARATOR
Intervention: Self‐focused kindness
Number of subjects: 159
Study 28395185 — intervention group
Group type: COMPARATOR
Intervention: Neutral control task
Number of subjects: 159
Study 25236397 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller pouch size group (10-20 ml)
Number of subjects: 76
Study 25236397 — intervention group
Group type: COMPARATOR
Intervention: Larger pouch size group (25-35 ml)
Number of subjects: 76
Study 21737162 — intervention group
Group type: COMPARATOR
Intervention: Moderate wine intake (up to 0.5L/day)
Number of subjects: 11248
Study 21737162 — intervention group
Group type: COMPARATOR
Intervention: Wine consumption up to 0.5L/day
Number of subjects: 11248
Study 21737162 — intervention group
Group type: COMPARATOR
Intervention: >0.5L/day wine consumption
Number of subjects: 11248
Study 21737162 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drinkers
Number of subjects: 11248
Study 21669298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine therapy for newly diagnosed extensive cGVHD
Number of subjects: 63
Study 18955740 — intervention group
Group type: EXPERIMENTAL
Intervention: Large jar
Number of subjects: 14
Study 18955740 — intervention group
Group type: EXPERIMENTAL
Intervention: Small jar
Number of subjects: 14
Study 18955740 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (large jar)
Number of subjects: 14
Study 18955740 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (small jar)
Number of subjects: 14
Study 15699772 — intervention group
Group type: EXPERIMENTAL
Intervention: RhuEPO 100 U/kg three times per week
Number of subjects: 40
Study 15699772 — intervention group
Group type: COMPARATOR
Intervention: Non-EPO group
Number of subjects: 40
Study 15699772 — intervention group
Group type: EXPERIMENTAL
Intervention: RhuEPO group
Number of subjects: 40
Study 12850361 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV PFP-2 vaccine
Number of subjects: 35
Study 12850361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10100251 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm capsulorhexis
Number of subjects: 51
Study 10100251 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm capsulorhexis
Number of subjects: 51
Study 10100251 — intervention group
Group type: COMPARATOR
Intervention: Both groups (4 mm and 6 mm capsulorhexis)
Number of subjects: 51
Study 8724922 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% glucose/sucrose solution at the rate of 0.6 g.kg‐1 (Body Weight).hr.‐1
Number of subjects: 7
Study 8724922 — intervention group
Group type: COMPARATOR
Intervention: Artificially flavored placebo
Number of subjects: 7
Study 1853142 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 226
Study 1853142 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 226
Study 6357106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol (10 ng/kg/day)
Number of subjects: 16
Study 6357106 — intervention group
Group type: COMPARATOR
Intervention: Calciferol (670 ng/kg/day)
Number of subjects: 16
Study 31725877 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertility consultations for females
Number of subjects: 100000
Study 31725877 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertility consultations for males
Number of subjects: 100000
Study 28284205 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D models of tetralogy of Fallot (n=18)
Number of subjects: 35
Study 28284205 — intervention group
Group type: COMPARATOR
Intervention: 2D drawings of tetralogy of Fallot (n=17)
Number of subjects: 35
Study 29231292 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 68
Study 29231292 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture (MA)
Number of subjects: 68
Study 24176063 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score tertiles for MVD (<5, ≥5 but <10, ≥10)
Number of subjects: 2627
Study 24176063 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score tertiles for SVD (<5, ≥5 but <10, ≥10)
Number of subjects: 2627
Study 24176063 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score for MVD
Number of subjects: 2627
Study 24176063 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score for SVD
Number of subjects: 2627
Study 22864880 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal locoregional resection (ELRR)
Number of subjects: 100
Study 22864880 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic total mesorectal excision (TME)
Number of subjects: 100
Study 19288005 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 38
Study 19288005 — intervention group
Group type: EXPERIMENTAL
Intervention: COPPEBVCAD
Number of subjects: 38
Study 19288005 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP
Number of subjects: 38
Study 17347903 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with 5-fluorouracil plus polysaccharide K
Number of subjects: 202
Study 17347903 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with 5-fluorouracil alone
Number of subjects: 202
Study 14506079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (bicycle training, up to 45 min at 80% peak heart rate, 3-4 days/week)
Number of subjects: 78
Study 14506079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 78
Study 14506079 — intervention group
Group type: COMPARATOR
Intervention: Control (flexibility activity)
Number of subjects: 78
Study 14506079 — intervention group
Group type: COMPARATOR
Intervention: Age-related decline
Number of subjects: 78
Study 11486115 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia to 32±1 degrees C for 12 to 72 hours
Number of subjects: 10
Study 11486115 — intervention group
Group type: COMPARATOR
Intervention: Concurrent controls (9 patients)
Number of subjects: 10
Study 9738164 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 2986
Study 2897987 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 16
Study 2897987 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16